Innovative Industrial Properties, Inc. (IIPR) Earnings Call Transcript
November 3, 2026
Earnings Call Speaker Segments
We appreciate everyone being on the call. With us today are Alan Gold, our Executive Chairman; Paul Smithers, President and Chief Executive Officer; David Smith, Chief Financial Officer; and Ben Regin, Chief Investment Officer. Prior to starting, I want to remind all of you that certain statements we make on today's conference call — including those concerning possible lease transactions covered by letters of intent — constitute forward-looking statements under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, and they carry risks and uncertainties. Actual outcomes could differ materially, and for a complete discussion of risk factors that might cause results to differ materially from what those forward-looking statements contain, we point you to our SEC filings, in particular our latest reports on Forms 10-K and 10-Q. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Additionally, during today's call we will discuss certain non-GAAP financial information, including FFO, normalized FFO, AFFO, and Adjusted EBITDA. That information, along with reconciliations to the most directly comparable GAAP financial measures, can be found in the investor relations section of our website at www.innovativeindustrialproperties.com, in our earnings release issued yesterday, and in our eight-K filed with the SEC. I'll now turn the call over to Alan.
Thanks, Eli. Good morning, everyone, and we appreciate you being with us on our Q3 2026 earnings call. During the third quarter we delivered yet another stretch of meaningful execution, and the highlights included further growth in our life science investments, robust leasing across the portfolio we already own, a substantial increase in AFFO per share compared with the second quarter, and capital allocation that stayed disciplined. The biggest item: in September we committed $245 million through a mezzanine loan as part of a lender syndicate, with IQHQ as the borrower, for Alewife Park — a top-tier life science campus located in Cambridge, Massachusetts, which ranks among the nation's foremost life science markets. This investment is highly accretive, and it extends the partnership we already have with IQHQ; we expect it to produce an average interest rate of roughly 15.8% across the loan's term. Along with our initial $270 million commitment to IQHQ and a further $30 million put in through the preferred equity structure in September, our total commitments to life sciences now stand at about $545 million. Once fully funded, life science investments should represent around 26% of our total annualized income. In our view, the present market environment keeps offering compelling chances to put capital to work in the life science sector at appealing entry points. The money we've put to work lately shows two things: we believe in this sector's fundamentals over the long haul, and we stay disciplined about growing our platform. Meanwhile, our team posted solid leasing numbers throughout our cannabis holdings. In the quarter, we signed new leases at six properties covering roughly 604,000 sq ft, and after the quarter closed we added another 270,000 sq ft. All told, that's about 874,000 sq ft of gross leasing activity from the start of the third quarter onward, which lifts gross leasing activity for the year so far to roughly 1.3 million square feet spanning 12 properties — about 15% of our entire portfolio. To begin with, demand remains robust throughout our holdings, which strengthens our conviction regarding the fundamental worth of our properties, and we have a lively set of further deals in progress. Our attention stays fixed on extending this positive trajectory, boosting occupancy levels, and preparing the portfolio to deliver solid results over the long haul. The quarter also brought robust financial results, since AFFO per share rose 7% from the prior quarter to reach $1.96, driven by ongoing collection of overdue rent from particular tenants; regarding financing, after the quarter closed we finished a public offering of our 9.25% Series B Preferred Stock totaling $54 million. The net proceeds are meant to cover either the full amount or part of what remains on our commitment tied to the Alewife Park mezzanine loan, along with general corporate needs. This deal shows once more that we can tap the capital markets to finance appealing, accretive investments and to back the ongoing expansion and diversification of our platform. Taken together, we believe these accomplishments underscore how strong our management team is and how well we can deploy capital into accretive investments while actively overseeing and maximizing value throughout the portfolio we hold today; we also feel that pairing our growing life science investments, our leasing momentum, and our financial flexibility puts us in a solid position for future growth and for generating long-term shareholder value. With that, I'll hand the call over to Paul. Paul?
Thanks, Alan. On the federal side, cannabis reform kept moving forward. During the summer, the DEA wrapped up its hearing concerning the proposed move to reschedule marijuana more broadly, from Schedule I to Schedule III. Although those proceedings are still open to additional administrative review, and we can't be sure about the timing or result of any final decision, we think federal reform could deliver meaningful benefits for operators, such as better economics and wider access to traditional sources of capital; we've also observed encouraging investment and M&A activity throughout the cannabis industry, as established operators seek expansion in attractive markets, including Pennsylvania, Ohio, New York, and Colorado. In our view, this activity indicates that well-capitalized operators stay committed to strategic growth and are actively putting money into markets with strong long-term fundamentals. Although financial challenges continue for certain operators, we keep taking decisive action across our portfolio. In the quarter, we regained possession of properties that had previously been leased to Parallel, PharmaCann, and The Cannabist Company. Through these transitions, we can pursue leasing opportunities, strengthen our tenant base, and improve overall portfolio performance. Now to the state level: Florida recently approved 22 additional vertically integrated medical cannabis licenses, a meaningful expansion of one of the country's largest medical cannabis markets; we believe new operators entering create opportunities for further investment and expansion in the state, including demand for mission-critical real estate. More broadly, regulated cannabis markets keep reaching significant milestones. In September, Massachusetts surpassed $10 billion in cumulative adult-use cannabis sales, while California has generated nearly $8.4 billion in cannabis tax revenue since 2018. These achievements underscore the scale and economic significance of established cannabis markets, even as operators continue to navigate a challenging environment. With that, I'll hand the call over to Ben for additional details on our portfolio activities.
Thank you, Paul. To start with our investment activity, our life science portfolio expanded this quarter as we closed $275 million in fresh commitments. We added a further $30 million of IQHQ preferred equity, and we closed a $245 million mezzanine loan commitment for Alewife Park, our flagship life science campus in Cambridge, Massachusetts. Alewife Park covers 27 acres and comprises three existing buildings with 392,000 sq ft in total, along with two pad-ready sites that could support as much as 364,000 sq ft of additional development. The current structures on the site are 78% leased to Lila Sciences, a company focused on AI-driven scientific discovery. Prior to our involvement, roughly $800 million had been put into the campus, and we think the property's quality, the tenant already in place, and its position within a top US life sciences hub provide a solid basis for an investment we expect to be accretive. Under the commitment's terms, we funded about $111 million when the deal closed, with the other $134 million anticipated to be drawn down between now and the end of Q4 2027. Across the loan's life, the average interest rate is projected at around 15.8%. The proceeds will go toward finishing construction, tenant build-outs, leasing up the space, and bringing the campus to stabilization. From where we sit, today's conditions continue to present compelling opportunities to enter life science real estate, especially for top-tier properties located in Boston, San Diego, and the Bay Area—the sector's core markets. According to JLL, demand across those three locations plus Raleigh-Durham climbed 44% compared with a year earlier, reaching almost 8 million sq ft during Q1 2026, fueled by improved biotech funding and biomanufacturing returning onshore. Against that background, we are busy broadening our acquisition pipeline and identify chances to put capital into high-quality assets throughout these core markets at appealing risk-adjusted returns. Turning to leasing, the quarter was our busiest so far, with considerable activity across numerous properties and markets. During Q3, we executed fresh lease agreements amounting to 604,000 square feet at six sites located in California, Massachusetts, New York, Ohio, and Washington. That forward motion continued into Q4, when we added a lease of 270,000 square feet at a Pennsylvania property, which pushes all leasing done from July onward to 874,000 square feet. On top of the deals already closed, we hold a set of further transactions that, in our view, are moving toward completion. We have contracts secured for three Colorado properties amounting to 72,000 sq ft, pending the license transfer and regulatory approval process, along with agreements spanning three properties that 4Front Ventures previously leased, adding another 374,000 sq ft; combined, these arrangements cover an extra 446,000 sq ft on top of the leases already signed. Such agreements are still contingent on customary due diligence, including licensing and regulatory approvals, and no guarantee exists that these talks or negotiations will lead to executed leases. With that said, I'll hand the call over to David.
Thanks, Ben. Total revenues for Q3 reached $64.9 million, rising from $63.3 million in Q2. Fresh lease agreements across our holdings boosted performance, and collecting previously overdue rent—largely tied to Battle Green and 4Front—added $0.15 per share to this quarter, as detailed fully in yesterday's press release. For the quarter, adjusted funds from operations (AFFO) totaled $54.8 million, or $1.96 per diluted share. The prior quarter stood at $53 million, or $1.83 per diluted share, with the factors just noted accounting for the change. Our life science investments likewise continue to deliver returns. During the quarter, we recorded $10.4 million in interest and dividend income connected to our financial investments in IQHQ, which contributed to total interest and other income reaching $14.3 million for the period. Only a handful of days of benefit from the recent Alewife investment were reflected in our Q3 results, and a larger favorable impact is expected to appear in Q4 results. Regarding capital markets activity, following the close of the quarter, we set the pricing on an underwritten public offering of 2.2 million shares of our 9.25% Series B Preferred Stock at $25 per share — generating $54 million in gross proceeds of perpetual capital at an attractive price. We intend to use those proceeds to support the mezzanine loan investment in the life science sector that we announced previously, while also giving us more flexibility to chase future investment opportunities. In our view, this transaction shows once more that we can tap multiple capital sources to support ongoing diversification and growth of our platform. Also after quarter end, we put in place a 90-day extension of our existing $87.5 million revolving credit facility, moving its maturity out to January of 2027; that extension gives us added flexibility to keep assessing our financing alternatives and managing our capital structure, since lender interest has been rising thanks to our continued diversification into the life science industry. In addition, as we pursue those diversification initiatives, the analyst coverage of our stock continues to grow. We are pleased that Stifel Nicolaus and Huntington Capital Markets have joined the roster of firms that cover our equity, taking the count of organizations covering IIP to eight. We appreciate the continued attention our company receives and anticipate interacting with a broader set of investors as we execute our strategy. Our balance sheet remains solid, supported by $142 million in total liquidity at the close of the quarter, and that amount excludes the $50 million preferred raise completed recently, which added another increase to total liquidity. The quarter ended with net debt to Adjusted EBITDA at 2.1 x, one of the lowest levels in the REIT sector, while net debt to total gross assets came in at a solid 19%. We remain focused on maintaining a conservative capital structure and a strong liquidity position, even as we selectively pursue attractive investment opportunities that support long-term growth. With that, operator, please open the call for questions.
Hello, and many thanks for the questions. So my first question concerns a few of the facilities you've repossessed. I appreciate the detail on the timing for the 4Front properties. When we consider the remaining properties—PharmaCann, Parallel, and the seven The Cannabist locations you took possession of in August and September—what's the best way to think about the timing for when you can get those released and start receiving rent revenue from them? Thanks.
Ben, would you like to handle that?
Yeah. Hey, Aaron. Sure thing. Yeah, historically, in our experience, that gap can run anywhere from six to 18 months — from finding a new tenant and starting the lease to transferring the license and going through the regulatory process. We feel really good about where we stand, especially with those particular assets. Looking at the vacancy we have right now, roughly two-thirds of it comes from our two Florida properties that are leased to Parallel — or were leased to Parallel previously. And the Florida market has done very well this year. They hit a new sales record in July, and we genuinely like the direction that market is heading, and we believe those assets are well set up for leasing activity going forward. And again, we also like to point out how capital-efficient we've been in re-tenanting these properties. Year-to-date, you're well under $10 a foot, all in, for commissions, TIs, landlord work — really everything involved in re-tenanting these assets.
Okay, great. Appreciate that color. Second question from me. I know last quarter we discussed the diversification split between cannabis and life sciences, but I wanted to dig deeper now into diversification within the life sciences sector specifically, and how you're thinking about additional opportunities in life sciences and having some diversification rather than concentration with the existing IQHQ and affiliates. Thanks.
Yeah, I think as we began the diversification process, we've, I think, done a good job. Our efforts so far have centered on investments into IQHQ, which we view as investments that are well-secured by the positions that exist at IQHQ. We believe that has provided us a very good window into what's happening in the life science industry, and we believe our diversification will keep going and that there are unique opportunities — not just within IQHQ, but across the broader life science industry — that we are definitely exploring and look forward to exploring down the road.
All right, great. Thanks for the call. I’ll get back in line.
Hi, everyone. Thanks for taking the question. I suppose to begin with, a portion of AFFO is still being generated by defaulted properties, whether that’s security deposits or payments that keep coming in. I guess the straightforward question is, do you expect quarterly AFFO to stay above that $1.90 payout?
David, why don’t you take that?
Bill, as you're aware, we turned in a really solid quarter. AFFO rose 7% from the prior quarter, which brought our payout ratio down to 97% this quarter. So we're quite pleased with those results. Looking ahead, we don't provide guidance. Historically, I believe we've done an excellent job of collecting those past due rent payments that customers owe us. Once again, that helped us this quarter. As you're pointing out, there were several benefits this quarter—which we lay out in our press release—that won't repeat, and PharmaCann, Parallel, and Battle Green were among those that benefited too.
Perhaps this leads naturally into a follow-up question; regarding Battle Green, control changed there, correct, with Vireo; so what ought we to anticipate from that going forward? We're able to see the payments in Q3, but what might those payments look like moving ahead from those assets?
Yeah. Hey, Bill, this is Ben. I mean, ordinarily we don't reveal lease terms for new leases. I mean, we truly saw that as, we had a tenant in default, and we were extremely aggressive about enforcing our rights under that lease and got interest from a new group that wanted to sign a lease for that asset before we could even finish that legal process; so I felt that really demonstrated the quality of the real estate and securing another tenant there so fast, and we're quite happy to have Vireo there and operating.
Thank you. I'll slip in one final question. Could you provide a bit more detail on the, I believe it was 16 terminated leases? It appears to me like a blend of retail and cultivation. So what type of properties were those, then? Did they sit around one particular tenant or one particular market? I'll pass it along now.
Yeah, no problem. Yeah, so of those, most of them, if you measure by square footage, are going to be the cultivation assets. Almost 50% of that is made up of the two Florida assets that we got back from Parallel. You also had a handful from PharmaCann, plus Battle Green and 4Front. I should also mention that several of those properties already have fresh leases in place. Take the Battle Green case we were just talking about — we signed a lease in New York that required ending PharmaCann's agreement and installing a new tenant. Then there's the 4Front asset in Washington, where, again, a new tenant is up and running and already paying rent. So once more, we're quite happy with how those deals came together.
All right. Thanks for resolving that confusion on my end. Thank you.
Thanks very much, and good morning, everyone. Perhaps to go back to Aaron's leasing question — your Q3 leasing activity set a record. Was that increase more a result of deals you'd been working on for a long time all concluding simultaneously, or has customer activity sped up? If it's the latter, what's causing the change, and how sustainable do you believe that demand is?
Yeah. Hey, Tom, this is Ben. I think it's a mix of those. I mean, real estate transactions are obviously lumpy by nature, so we had several of those all converge in the same quarter. I think we're still happy with how quickly the re-tenanting has been moving. I would say there's some optimism out there, and we're seeing more M&A activity among the groups that are getting back on offense in certain states where they want to expand, and they see the value in the real estate we hold. Going forward, the vacancy that's left at this point is a little more than 800,000 sq ft, and the majority of it—two-thirds—is our two Parallel assets in Florida; that's where our focus will be. As we mentioned earlier, we feel really good about the Florida market, which set a new monthly sales record in July, along with a 20% year-over-year increase in sales in the Florida market. They’ve just granted a set of new licenses, and with those two assets we believe our position is quite strong.
Great, thanks for that, Ben. Perhaps a final question from me, looking at the IQHQ investment and focusing on the preferreds. When you originally reviewed that investment with IQHQ, along with the milestones tied to the Series G fundings and the draws the company would have taken—how does performance stack up against your original underwriting or expectations? Does the extra $30 million you contributed this quarter reflect stronger execution or higher costs?
As we laid out in the prepared remarks, the life science sector keeps getting better, and that means that. IQHQ appears to be gaining from that growth — it has a stronger position and more leasing momentum, especially at Alewife, which is now up to 78%, and there may be added demand for their emerging projects. Their success shows at the Redwood City Elco Yards property, and some fresh leasing activity is also starting to appear in the San Diego market. They are performing — that's the first point. Second, the extra capital investment was a chance we had and seized; they had favorable news and capital needs, and we had funds on hand that we felt were attractively priced and highly accretive to IIPR.
Understood. I appreciate the responses. Thank you all.
Morning, everyone. David, to frame the revenue question somewhat differently, is there anything more in the way of security deposits past the $3.8 million from the third quarter that you could draw down during the fourth quarter for tenants who aren't paying right now or whose leases are in transition and haven't commenced yet, and so on? Or have you by now used up the security deposits tied to those tenants named in the earnings release?
Yeah, absolutely. Rob, with regard to four of those five tenants, everything there is completely used up. There are still a few properties with The Cannabist Company where some security deposits remain available to us.
All right, that's useful. Thanks. Alan, how would you suggest we think about the odds that you'll pick up the extra $155 million of the IQHQ mezz loan, and in your view, what determines that?
Well, it isn't a matter of picking it up. As they keep building out the improvements for the Lila lease, they'll draw down that additional $155 million; our expectation is that it gets drawn down gradually, absent any changes.
So on top of that $134 million which is still undrawn, that gives you an incremental draw of $289 million, right? Because it was $245 million, with $111 million taken at closing and $134 million left under that $245 million, and then you also had the option to buy the $155 million from a different lender on identical terms.
Oh, I understand now. Sorry about that. I didn't follow. Alright, please continue. Regarding our opportunity to pick up that extra amount, I'd say it's a possibility; it's written into our agreement. That's what we're aiming to do. Making that call requires us to have the capital on hand. Should an opportunity arise and we conclude it's the wisest use of our funds, we'll definitely examine it. Were such a deal to happen, it would be highly accretive.
All right. So I suppose the final question is just to follow up on that point. At this stage, how is the board viewing the maximum investment in IQHQ as it keeps ratcheting up? I mean, are we approaching a point where, if you did draw down that additional 155, that would be the end of it? Or does the board still believe there remains room for incremental investment there?
Well, I mean, when you consider the opportunity, we believe the assets IQHQ holds are of high quality, which explains why we made an additional investment in the Alewife transaction. That is merely one instance of a very high-quality asset with a tremendous amount of leasing already in place plus additional leasing activity. Should other opportunities arise, I think the board would look at them and certainly would consider them. We don't view our investments as really just investments in IQHQ, but tangentially also as investments in the life science industry, and as a vehicle for us to diversify our portfolio away from just the cannabis focus that we had. This diversification we're undertaking has increased our access to new lenders and new capital sources; so it has proven to be what the board had thought it would be, which is a very good move for the company, and to give us greater access to capital.
All right.
And it's likely that, should further opportunities arise, we'll most likely keep doing so, since our wish for diversification exceeds the level where we currently stand.
All right, I was wrong. One final question, David. Given this new preferred issuance, can you tap it through an ATM and sell gradually there? Or would returning to market for more of that series require a fully marketed offering?
No, that new Series B does give us ATM capability; so, as you're suggesting, we possessed that capacity with our Series A. Demand was very strong and we succeeded in raising perpetual capital through that Series A this year. The Series B carries that same ability, as you know.
Okay. Thanks, guys. Appreciate the time.
Thank you.
Thank you. To start, I want to express appreciation to everyone who has joined us on today's call and for those excellent questions. My thanks also go out to our team for their tremendous effort during this past quarter, and we definitely look forward to what lies ahead for IIPR. With that said, thanks to you all, and we'll bring the call to a close.
This concludes today's call. Thank you for attending. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Innovative Industrial Properties, Inc. transcript - plus 133,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Innovative Industrial Properties, Inc. earnings transcripts and 133,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.